secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K/A
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001104659-24-118858
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium completes Ironshore acquisition; discloses Ironshore's $49.8M net loss for 2023 and $67.4M for H1 2024
--------------------------------------------------------------------------------

- Acquisition closed Sept 3, 2024; Ironshore's JORNAY PM (ADHD) product revenue $78.6M in 2023, $43.8M in H1 2024.
- Ironshore total assets $84.7M, total liabilities $442.3M, shareholders' deficit $(357.6)M at June 30, 2024.
- Ironshore notes payable (current + non-current) $149.8M at June 30, 2024; asset-backed lending $12.6M.
- Deferred royalty obligation $123.5M at June 30, 2024; warrant liability $8.3M; derivative liability $36.0M.
- Ironshore's net loss $(49.8)M in 2023 and $(67.4)M in H1 2024, with operating losses since inception.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465924118858/0001104659-24-118858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465924118858/tm2428082d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-118858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer